轻度创伤性脑损伤的液体生物标志物与神经影像:急诊医学当前应用与未来方向
轻度创伤性脑损伤是急诊常见就诊原因,当前处理重点在于判断是否需要头颅CT扫描和/或神经外科干预。越来越多证据认识到约20%-40%的患者(包括CT阴性者)会出现持续数月至数年的症状,常称为脑震荡后综合征。血液生物标志物有潜力比当前临床决策规则更好地对患者进行影像学需求的风险分层,但广泛采用前需进一步评估其临床效用。采用临床序列和先进定量方法的MRI可在多达30%的患者中检出CT不可见的病灶,可能至少部分解释部分持续存在的问题。急性生物标志物(影像、血液或其他)若能在早期识别持续功能缺损风险更高的患者,将有助于随访护理和资源分配的个体化。
要点
- 轻度创伤性脑损伤患者中约20%-40%(包括CT阴性者)会发展为持续数月至数年的症状,常称为脑震荡后综合征。
- 血液生物标志物有潜力比当前临床决策规则更好地对神经影像需求进行风险分层,但广泛采用前需进一步评估临床效用。
- 采用临床序列和先进定量方法的MRI可在多达30%的患者中检出CT不可见的病灶,可能至少部分解释部分持续问题。
- 急性生物标志物(影像、血液或其他)若能在早期识别持续功能缺损风险更高的患者,可促进随访护理和资源分配的个体化。
适用人群与场景
- 急诊科就诊的轻度创伤性脑损伤患者
研究设计与关键结果
- 综述指出约20%-40%的轻度创伤性脑损伤患者(包括CT阴性者)会发展为持续数月至数年的症状,常称为脑震荡后综合征。
- 血液生物标志物有潜力比当前临床决策规则更好地对神经影像需求进行风险分层,但广泛采用前需进一步评估临床效用。
- 采用临床序列和先进定量方法的MRI可在多达30%的患者中检出CT不可见的病灶,可能至少部分解释部分持续问题。
证据类型、等级与局限
- 证据类型:综述
- 局限:原文未报告局限性
对床旁实践的改变
- 作者认为,急性生物标志物(影像、血液或其他)若能在早期识别持续功能缺损风险更高的患者,将有助于随访护理和资源分配的个体化。
- 作者指出,血液生物标志物有潜力比当前临床决策规则更好地对神经影像需求进行风险分层,但广泛采用前需进一步评估其临床效用。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Mild traumatic brain injury is a common presentation to the emergency department, with current management often focusing on determining whether a patient requires a CT head scan and/or neurosurgical intervention. There is a growing appreciation that approximately 20%-40% of patients, including those with a negative (normal) CT, will develop ongoing symptoms for months to years, often termed post-concussion syndrome. Owing to the requirement for improved diagnostic and prognostic mechanisms, there has been increasing evidence concerning the utility of both imaging and blood biomarkers.Blood biomarkers offer the potential to better risk stratify patients for requirement of neuroimaging than current clinical decisions rules. However, improved assessment of the clinical utility is required prior to wide adoption. MRI, using clinical sequences and advanced quantitative methods, can detect lesions not visible on CT in up to 30% of patients that may explain, at least in part, some of the ongoing problems. The ability of an acute biomarker (be it imaging, blood or other) to highlight those patients at greater risk of ongoing deficits would allow for greater personalisation of follow-up care and resource allocation.We discuss here both the current evidence and the future potential clinical usage of blood biomarkers and advanced MRI to improve diagnostic pathways and outcome prediction following mild traumatic brain injury.
参考来源
- Newcombe V, Richter S, Whitehouse DP, et al. Fluid biomarkers and neuroimaging in mild traumatic brain injury: current uses and potential future directions for clinical use in emergency medicine. Emerg Med J. 2023. PMID: 37438096. doi:10.1136/emermed-2023-213111
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。